FTC Order to Bar ZyCal Bioceuticals from Deceptive Health Marketing

FTC Order to Bar ZyCal Bioceuticals from Deceptive Health Marketing Company claimed its product could grow bone and cartilage, relieve joint pain The Federal Trade Commission today announced an order settling a 2020 federal lawsuit against defendants ZyCal Bioceuticals Healthcare Company, Inc. (ZyCal) and its president James J. Scaffidi, which charged them with deceptively claiming that their products grow bone and cartilage and relieve joint pain. View Press Release More news from the FTC

p>

---

To update or delete your subscription at any time, visit your subscriber preferences page. If you have questions or problems with the subscription service, please contact subscriber support. This is a free service provided by the Federal Trade Commission.

---

This email was sent to jtrent238.test@blogger.com using GovDelivery Communications Cloud on behalf of: Federal Trade Commission · 600 Pennsylvania Ave., NW · Washington, DC 20580 · 1-877-382-4357